单唾液酸神经节苷脂联合长春西汀治疗急性脑梗死的临床疗效分析及安全性研究

摘要

Objective To evaluate clinical therapeutic efficacy and safety of joint application of Monosialotetrahexosylganglioside Sodium and the Vinpocetine in patients with acute cerebral infarction.Methods 60 patients with acute cerebral infarction, admitted to Wuxi People's Hospital Attached to Nanjing Medical University from January 2013 to July 2015, were randomly divided into observation group(n=30) and control group(n=30).They were both treated by identical basis therapy, such as antiplatelet, dilute blood viscosity, neurotrophy therapy and symptomatic treatment.The patients in the observation group were treated by joint application of Monosialotetrahexosylganglioside Sodium and the Vinpocetine on the identical basis therapy.On the pretherapy and post-treatment day, the National Institutes of Health Stroke Scale (NIHSS), Barthel Index(BI), neuron specific enolase(NSE), hemodynamic indexes and efficiency of clinical treatment in these patients were performed.Blood routine examinations, hepatorenal function and ECG were monitored.CT SCan was employed for ICH and drug relative hemorrhage and adverse drug reaction( ADR) were recorded in detail.Results After treatment, 2 groups of NIHSS, BI score, blood rheology index, NSE level compared with before treatment improved significantly, the difference was significant (P<0.05).NSE, hemorheology and total effective rate of the observation group were better than the control group(P<0.05).The clinical total effective rate was 93.3% in treatment group and 76.6% in control group (P<0.05).During therapy period, There was no adverse reaction in 2 groups.Conclusion Joint application of Monosialotetrahexosylganglioside Sodium and the Vinpocetine is safe and effective in treating patients with acute cerebral infarction, through improving the clinical neurological deficits, blood rheology indicators and activity of daily living.%目的：观察联合应用单唾液酸神经节苷脂与长春西汀对急性脑梗死患者的临床疗效及安全性。方法选择南京医科大学附属无锡人民医院2013年1月至2015年7月收治的急性脑梗死患者60例，随机分为2组，应用单唾液酸神经节苷脂联合长春西汀加常规治疗为治疗组，常规药物治疗为对照组。比较治疗前后2组患者神经功能缺损评分（ NIHSS）、Barthel指数（ BI）评分、血液流变学指标、血清神经元特异性烯醇化酶（ neuron-specific enolase，NSE）水平及治疗有效率，监测治疗过程中药物相关的不良反应。结果2组治疗后NIHSS、BI评分、血液流变学指标、NSE水平与治疗前相比改善明显（P＜0.05）；相比于对照组，治疗组各指标改善明显，差异显著（P＜0.05）。临床总有效率：治疗组为93.3％，对照组为76.6％，2组总有效率比较差异有统计学意义（P＜0.05）。2组均无不良反应。结论单唾液酸神经节苷脂联合长春西汀治疗急性脑梗死安全、有效，可有效促进患者神经功能恢复和提高日常生活能力。